Brief: Kancera Receives Approval From Fimea And Etisk Kommittee To Start Last Phase Of Ib-Program For KAND567

Novakand Pharma AB

05/02/2020 07:22

Feb 5 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA AB - HAS RECEIVED APPROVAL FROM FIMEA AND ETISK
KOMMITTEE TO START LAST PHASE OF IB-PROGRAM FOR KAND567
    * KANCERA AB - CO ESTIMATES THAT RESULTS OF THE STUDY MAY
BECOME
AVAILABLE IN MARCH 2020

Source text for Eikon:  ID:nWkr4YMgpy 
Further company coverage:  KANC.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))